Hypothesis-Generating Brief: Sirtuin Intervention Aging Effects

Hypothesis-Generating Brief: Sirtuin Intervention Aging Effects

Abstract

Evidence-honesty note: 36/41 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 38/41 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on sirtuin intervention aging effects across 41 accepted source papers and 1394 high-confidence extracted claims.

The evidence profile contains 3 direct clinical sources, 37 adjacent clinical sources, and 1 mechanistic or model-system source, with 116 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the muscle function, immune and inflammation outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that sirtuin intervention aging effects remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Introduction

This synthesis evaluates evidence on sirtuin intervention aging effects across 41 included source papers and 1394 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, indirect interventional hard-endpoint evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 3 direct clinical sources, 37 adjacent clinical sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The thesis is: Across 41 curated reference papers, the evidence base for Sirtuin shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: muscle function, immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Sirtuin anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

Background

The background evidence for sirtuin intervention aging effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Werida 2023, Daneshi-Maskooni 2017, Bo 2018 are interpreted separately from mechanistic studies such as Krekora 2026, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the contextual adjacent evidence outcome class; null signals around the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes; and negative or adverse signals around the muscle function, immune and inflammation outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-sirtuin_intervention_aging_effects-v06-DAILY-2026-06-21T20-50-48Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-21.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• sirtuin intervention aging effects aging
• sirtuin intervention aging effects older adults
• sirtuin intervention aging effects randomized controlled trial
• sirtuin aging
• sirtuin older adults
• sirtuin randomized controlled trial
• intervention aging aging
• intervention aging older adults
• intervention aging randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses sirtuin intervention aging effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 189 records in the receipt-candidate union, 69 were classified as source candidates and 41 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	189
Classified source candidates	69
No extractable claims	40
None-only claim binding	9
Mixed partial-or-none claim-binding candidates	55
Partial-only claim-binding candidates	10
Strict high-confidence sources	6
Admitted final sources	41

Admission-bucket note: The funnel rows are audit categories, not an additive conservation table. No-extractable-claim, mixed partial-or-none, partial-only, and admitted-final-source counts can be equal or overlap because they describe different screening and claim-binding states; final source admission is the retained-source count after deduplication and eligibility, not the complement of any one exclusion row.

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Evidence Landscape

Source directness breakdown: 3/41 retained sources directly address the stated topic and aging-relevant hard endpoints; 38/41 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims.

Source Classification Map

• Additional corpus sources included animal/preclinical evidence; Nowak-Szwed 2025: outcome=Cardiometabolic; directness=indirect; tier=B2.
• Garcia-Martinez 2023: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.
• Wu 2022: outcome=Cardiometabolic; directness=indirect; tier=B2.
• Zhang 2025: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.
• Werida 2023: outcome=Contextual Adjacent Evidence; directness=direct; tier=A1.
• Nguyen 2026: outcome=Population / prevalence; directness=indirect; tier=B2.
• Nikooyeh 2021: outcome=Cardiometabolic; directness=indirect; tier=B2.
• Monge 2025: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

Additional corpus sources included animal/preclinical evidence; substantive evidence synthesis: The manifest includes 41 retained sources, 3 direct-source row(s), and directional coding across negative=2, null=36, positive=1, unclear=2. Representative source-level signals are: Nowak-Szwed 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; claims=124; Wu 2022: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; claims=106; Werida 2023: outcome=Contextual Adjacent Evidence; direction=positive; directness=direct; tier=A1; claims=80; Shi 2025: outcome=Muscle Function; direction=negative; directness=indirect; tier=B2; claims=11; Noureldein 2015: outcome=Immune and Inflammation; direction=negative; directness=review; tier=B1; claims=1; Garcia-Martinez 2023: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; claims=106; Zhang 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; claims=82; Nguyen 2026: outcome=Population / prevalence; direction=null; directness=indirect; tier=B2; claims=65. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.

Key Findings

Additional corpus sources included animal/preclinical evidence; key findings from source synthesis: First, the strongest positive or favorable signals are treated as narrow source-level signals, not broad clinical proof (Nowak-Szwed 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; claims=124; Wu 2022: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; claims=106; Werida 2023: outcome=Contextual Adjacent Evidence; direction=positive; directness=direct; tier=A1; claims=80). Second, negative, mixed, unclear, or no-directional-signal rows are given equal interpretive weight (Shi 2025: outcome=Muscle Function; direction=negative; directness=indirect; tier=B2; claims=11; Noureldein 2015: outcome=Immune and Inflammation; direction=negative; directness=review; tier=B1; claims=1; Garcia-Martinez 2023: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2; claims=106). Third, the bounded conclusion follows from the balance of source direction, outcome class, evidence tier, and directness rather than from source count alone.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=22; claims=779	no extracted directional signal in 21/22 sources	2 direct; 18 indirect; 1 protocol; 1 review	limited corpus depth in this outcome class
Cardiometabolic	n=9; claims=377	no extracted directional signal in 7/9 sources	1 direct; 8 indirect	limited corpus depth in this outcome class
Population / prevalence	n=4; claims=114	no extracted directional signal in 4/4 sources	4 indirect	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=52	no extracted directional signal in 1/2 sources	1 indirect; 1 review	limited corpus depth in this outcome class
Muscle Function	n=2; claims=49	no extracted directional signal in 1/2 sources	2 indirect	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=1; claims=22	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Longevity	n=1; claims=1	no extracted directional signal in 1/1 sources	1 mechanistic	single-source slice; hypothesis-generating

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Results Summary

• Contextual Adjacent Evidence: n=22; claims=779; no extracted directional signal in 21/22 sources | directness: 2 direct; 18 indirect; 1 review; 1 protocol; main limitation: directionally heterogeneous.
• Cardiometabolic: n=9; claims=377; no extracted directional signal in 7/9 sources | directness: 1 direct; 8 indirect; main limitation: directionally heterogeneous.
• Population / prevalence: n=4; claims=114; no extracted directional signal in 4/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor.
• Muscle Function: n=2; claims=49; no extracted directional signal in 1/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor.
• Dosing and Pharmacokinetics: n=1; claims=22; no extracted directional signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.
• Immune and Inflammation: n=1; claims=1; adverse or limiting signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

Additional corpus sources included animal/preclinical evidence; the cardiometabolic outcome class contains the largest concentration of curated evidence, comprising nine observational or interventional reports that vary in design, directness, and reported effect direction. Daneshi-Maskooni 2017 is the only clinical RCT in this class, randomizing adults with nonalcoholic fatty liver disease and obesity to receive green cardamom versus placebo with cardiometabolic and sirtuin-1 endpoints. Lorente 2026, Bielach-Bazyluk 2025, Nowak-Szwed 2025, Lapatto 2026, Shi 2020, and Wu 2022 supply mechanistic or biomarker-level indirect evidence spanning salivary SIRT1 in periodontitis, circulating SIRT1 in chronic kidney disease, SIRT4/SIRT6 modulation by empagliflozin post-myocardial infarction, NAD+/Sirtuin methylation in BMI-discordant monozygotic twins, statin-induced SIRT6 suppression, and a broad narrative review of the sirtuin family.

Quantitative findings cluster around null or biomarker-level effects rather than hard clinical events.

Mechanistically, the cardiometabolic evidence is anchored in indirect biomarker work rather than clinical RCT confirmation of functional endpoints. Biscetti 2024 extends the human substrate by treating baseline serum SIRT1 as a predictor of cardiovascular outcomes in diabetic limb-threatening ischemia, generating the kind of prognostic biomarker signal that downstream trials could test as a stratification factor. The mechanistic substrate underlying these functional findings therefore combines statin-SIRT6-miRNA crosstalk, obesity-driven NAD+ epigenetic remodelling, and circulating SIRT1 as a candidate outcome predictor.

Within-corpus tensions are dominated by the directness gap separating the lone clinical RCT from a field of indirect observational and preclinical reports. Daneshi-Maskooni 2017 is the only direct-design study in this outcome class and is positioned against eight indirect studies: Biscetti 2024, Bielach-Bazyluk 2025, Nowak-Szwed 2025, Lorente 2026, Lapatto 2026, Shi 2020, Nikooyeh 2021, and Wu 2022, each of which measures sirtuin biology without confirming a hard clinical endpoint attributable to a sirtuin-targeted intervention. The RCT-protocol design of Daneshi-Maskooni 2017 versus the prospective prognostic design of Biscetti 2024 illustrates how the same outcome class can be populated by studies whose evidentiary roles do not overlap: the RCT tests intervention-driven SIRT1 change, whereas the cohort asks whether baseline SIRT1 predicts later events.

Indirect human cohorts and translational studies populate the contextual class with additional quantitative signals.

Population / prevalence Outcomes

Additional corpus sources included animal/preclinical evidence; four observational cohort studies, indexed as Nguyen 2026, Bodis 2019, Poniatowski 2026, and Tsai 2021, framed the deficiency-prevalence evidence base for the Sirtuin synthesis, each measuring sirtuin abundance or activity in adult human or model-adjacent tissue rather than testing a therapeutic intervention (Nguyen 2026; Bodis 2019; Poniatowski 2026; Tsai 2021). The endpoint class across these reports was therefore descriptive biomarker quantification in deficiency-associated states, not a randomized sirtuin-activating intervention.

Quantitative findings were heterogeneous across the four cohorts. Across the full table of per-study p-values, the four cohorts together yielded a wide effect-direction distribution, consistent with the brief's overall characterization of mixed human evidence for sirtuin biology in aging-relevant deficiency states.

Mechanistically, the source signal aligns with the broader sirtuin literature in which SIRT1, SIRT3, and SIRT6 function as NAD+-dependent deacylases regulating mitochondrial respiration, glycolysis, and epithelial-mesenchymal transition, and the four included cohorts each targeted one of these specific isoforms in clinically defined deficiency states. Nguyen 2026 linked endothelial sirtuin abundance to PBMC mitochondrial respiration, Poniatowski 2026 quantified SIRT1 and SIRT3 in biofluids as candidate biomarkers of neuronal injury, and Tsai 2021 implicated SIRT6 in KLF10-deficient pancreatic adenocarcinoma glycolysis and metastasis (Nguyen 2026; Poniatowski 2026; Tsai 2021). Bodis 2019 extended the same logic to reproductive-age women, where serum and follicular fluid sirtuin concentrations were profiled against IVF-cycle characteristics. The convergence across these mechanistic human studies and preclinical data is that sirtuin deficiency tracks with the relevant pathophysiology — vascular aging, traumatic CNS injury, tumor glycolysis, and ovarian aging — but no source in this outcome class tested whether restoring sirtuin activity altered a clinical endpoint.

Within-corpus tensions in this outcome class run along the indirect-versus-direct axis rather than between intervention trials, because the four included reports are all descriptive biomarker studies. Poniatowski 2026 also documented a P > 0.05 comparison embedded within a set of highly significant TBI-versus-control contrasts. In Part A, participants were randomized 6:2 to SP-624 versus placebo, providing a 3:1 allocation ratio within each single ascending dose (SAD) cohort and framing the dose-exposure relationship that subsequent human work must situate against. The study enrolled healthy adults and tested both single and multiple ascending oral doses, with the stated endpoints of safety, tolerability, and pharmacokinetics rather than clinical anti-aging outcomes. This positions SP-624 as a first-in-class oral SIRT6 activator whose human pharmacokinetic profile is now characterized, even as the corresponding efficacy portfolio in aging endpoints remains to be built.

Immune and Inflammation Outcomes

The within-corpus effect direction for the immune outcome class is therefore uniformly negative, and the corresponding effect direction tag in the source is negative (Noureldein 2015).

Because the source is a clinical systematic review in type 2 diabetes patients rather than a preclinical mechanistic study, the immune signal is best characterised as clinically anchored human evidence with mechanistic coherence via the SIRT1 / fetuin A axis (Noureldein 2015). The review's design therefore provides a directness label of 'review' for the immune class, with the human RCT substrate sitting upstream of the mechanistic interpretation (Noureldein 2015).

Within-corpus tensions specific to the immune class are not enumerated in the cross-study disagreement map because no same-outcome non-orthogonal pairs were identified for this outcome, so the immune subsection is reported as a single coherent direction-of-effect finding rather than as a set of competing claims (Noureldein 2015). The boundary condition that should be flagged in discussion is that the immune signal is drawn from a single systematic review with a 'review' directness label and an effect direction tagged as negative, so the strength of the immune claim is anchored to one indexed source rather than distributed across multiple independent primary trials (Noureldein 2015). the evidence synthesis (Per-Study Endpoint Evidence) carries the full per-study numeric tuples for the immune outcome class, and the prose above references rather than restates every value (Noureldein 2015).

The single curated trial in the immune-inflammation outcome class is an observational-cohort analysis within a randomized, double-blind, placebo-controlled clinical trial of cinnamon supplementation in type 2 diabetes patients, evaluating systemic inflammation factors, NF-kB, and Sirtuin-1 (SIRT1) expression. The underlying trial enrolled 44 adult participants with type 2 diabetes. Endpoint assessment targeted circulating inflammatory mediators and SIRT1 pathway readouts, with NF-kB as the principal mechanistic node. Directness for the sirtuin-aging synthesis is indirect, because the trial tested a nutraceutical stimulus rather than a direct sirtuin-activating compound (Davari 2020).

Quantitative findings from the analysis are mixed, with several null contrasts and a small set of significant associations. The effect-direction annotation is null, indicating that despite isolated significant p-values, the overall pattern does not support a coherent anti-inflammatory effect of the intervention. The Evidence Snapshot lists each per-endpoint p-value for transparency so the prose can summarize rather than enumerate.

Mechanistically, the trial interrogates an NF-kB–SIRT1 axis that is plausibly relevant to inflammaging, because SIRT1 is a known negative regulator of NF-kB transcriptional activity in preclinical models. The clinical RCT finding of scattered significant p-values (P = 0.008, P < 0.05, P = 0.02) against a largely null pattern suggests that, in human type 2 diabetes patients, modulating this axis through the chosen nutraceutical does not produce a consistent anti-inflammatory signature. By contrast, mechanistic substrate supporting SIRT1–NF-kB crosstalk derives from preclinical work not represented in the current source set, so the human-RCT signal should not be over-extrapolated. The inflammation outcome class therefore rests on one indirect clinical RCT with a null summary verdict (Davari 2020).

Within-corpus tensions cannot be enumerated for the immune-inflammation class because only one source is present in the corpus for this outcome, and the cross-study disagreement map contains no same-outcome non-orthogonal pairs. As a result, the strongest claim that the evidence base supports is the null directional verdict from Davari 2020, qualified by the presence of individual endpoints reaching P < 0.05. No opposing clinical-RCT source is available to adjudicate whether those isolated significant p-values are reproducible, and the indirect directness label further limits confidence in extrapolating to a direct sirtuin-activating intervention. The honest reading is that immune and inflammatory readouts remain under-tested in the curated corpus (Davari 2020).

The contextual-other outcome class in the curated corpus is represented by the same randomized, double-blind, placebo-controlled clinical trial of cinnamon supplementation in type 2 diabetes patients that supplies the immune-inflammation data, with endpoints extending to broader systemic and pathway-level readouts. The trial population comprised 44 adult type 2 diabetes patients, and endpoint assessment captured multi-domain markers beyond classical inflammation. Directness to the sirtuin-aging synthesis is again indirect, because the active intervention was a nutraceutical, not a canonical sirtuin-activating compound (Davari 2020).

Per-endpoint p-values are itemized in the Evidence Snapshot to avoid prose enumeration.

Mechanistically, the contextual endpoints sit downstream of the same SIRT1/NF-kB axis interrogated in the inflammation panel, so a coherent interpretation requires that any nutraceutical-induced SIRT1 modulation should propagate to systemic pathway readouts. The clinical RCT evidence does not show such propagation in a consistent direction, which constrains how strongly the mechanistic plausibility case can be translated into human-physiology expectations. By contrast, broader mechanistic substrate supporting sirtuin involvement in aging biology is widely discussed in the field but is not represented as an independent source in the curated corpus. The current evidence base therefore offers indirect, null-dominant support for contextual mechanistic effects of the trial intervention (Davari 2020).

The strongest positive findings that the corpus can support are the isolated endpoints reaching P = 0.008 and P < 0.05 in the same Davari 2020 analysis, alongside the borderline P = 0.06 and P = 0.055 contrasts, which together indicate that some pathway-level readouts are responsive even though the directional summary is null.

The source does not provide p-values, hazard ratios, or sample size, and the effect direction field is recorded as null because the cited source excerpt describes biological positioning rather than a quantified intervention effect.

Consequently, this outcome class is reported qualitatively rather than as a numeric pooled effect.

No additional longevity numerics (survival curves, hazard ratios, log-rank p-values) are present in the included source set, so the Results subsection cannot report an effect size, confidence interval, or p-value for any longevity endpoint. Effect direction is therefore recorded as null on the source, not as a verified absence of effect, and downstream synthesis must treat any longevity claim as hypothesis-generating rather than confirmed.

Because the evidence is preclinical and mechanistic rather than a clinical RCT, the mechanistic substrate is well articulated but is not paired with a human longevity endpoint in this corpus. The absence of paired clinical RCT longevity data is itself a finding: the human longevity boundary condition for sirtuin intervention remains unmapped in the accepted evidence.

Contextual Adjacent Evidence Outcomes

Mechanistically, the contextual class spans three converging pathways: redox homeostasis (Garcia-Martinez 2023, Werida 2023, Sokrateva 2026), epigenetic remodeling via H3K56 acetylation (Bo 2018), and autophagy/ferroptosis-coupled vascular senescence (Zhang 2025). Preclinical and translational data in Zhang 2025 reported a significant decrease in aortic senescence-associated β-galactosidase (SA-β-gal) in vivo, with significance levels of P < 0.001, P < 0.05, and P < 0.01 attributed to EGCG-driven SIRT1 signaling (source id: Zhang 2025).

Within-corpus tensions in this class center on the directness gap between human RCTs and observational cohorts and on a partial effect-direction conflict between the two direct RCTs. The synthesis-level tensions within this class therefore consist of the single null-vs-positive direct RCT pair (Werida 2023 vs Bo 2018) together with the broader pattern of direct RCT signals sitting alongside indirect observational evidence, rather than a numerically enumerated cross-study disagreement count.

Contextual Adjacent Evidence remains a separate Results slice (n=22; claims=779; no extracted directional signal in 21/22 sources; 2 direct; 18 indirect; 1 protocol; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Muscle Function Outcomes

In animal/preclinical evidence, Shi 2025, by contrast, contributes no reported p-values but is tagged with a negative effect direction on the muscle function outcome class (Shi 2025). The combined evidence base thus contains one null human-cohort signal and one negative mechanistic signal, without a positive human effect estimate available in the sources.

By contrast, Cho 2022 frames sirtuin levels as a biomarker response to acute exercise intensity rather than as a therapeutic target, so its mechanistic relevance to chronic sirtuin-intervention aging effects is indirect.

Additional corpus sources included animal/preclinical evidence; the two studies are not directly comparable: Cho 2022 evaluated sirtuin biomarker responses to acute exercise in healthy young men, whereas Shi 2025 evaluated a pharmacological irisin intervention in a glucocorticoid-induced sarcopenia model. Per the Evidence Snapshot, neither source provides a positive human muscle-function effect estimate, so the corpus as constituted supports a mixed-to-null verdict for sirtuin-intervention effects on muscle function, with mechanistic plausibility but no confirmed positive human signal.

Dosing and Pharmacokinetics Outcomes

The Rigdon 2024 report provides a dosing framework rather than a clinical effect estimate: no p-values are reported in the source for pharmacokinetic endpoints, consistent with the descriptive PK/safety design. The 6:2 active-to-placebo allocation means each SAD cohort is small, which limits the ability of the trial to detect rare adverse events but is sufficient for a standard first-in-human PK characterization. Because the thesis is narrowly scoped to safety, tolerability, and pharmacokinetics, downstream syntheses should not treat SP-624 exposures as validated anti-aging doses. The available quantitative substrate for this outcome class is therefore architectural (allocation ratio, design, dose-escalation structure) rather than inferential.

Mechanistically, the availability of a characterized oral SIRT6 activator in healthy adults matters for the broader sirtuin-intervention aging program because it defines the human-exposability boundary for this target class. Sirtuin activators have been proposed to act through NAD+-dependent deacylation, mitochondrial biogenesis, and DNA-damage response modulation, and the Rigdon 2024 PK profile is what links that mechanistic substrate to a feasible oral dosing regimen in humans. Without a human PK anchor, mechanistic claims about SIRT6 activation in preclinical models remain disconnected from clinical translation; with it, the field gains a tractable molecule against which downstream functional endpoints can be tested. The source does not, however, report downstream pharmacodynamic biomarkers, so the mechanistic bridge is inferential rather than measured.

The tension to flag is instead cross-domain: Rigdon 2024 establishes that a SIRT6 activator is orally exposable in humans, while the outcome classes downstream of dosing — including muscle function, immune, and cardiometabolic — remain mechanistically plausible but not yet supported by the dosing source itself.

Dosing and Pharmacokinetics remains a separate Results slice (n=1; claims=22; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Longevity Outcomes

Directness is categorized as mechanistic (Krekora 2026), meaning the source contributes biological substrate and not a clinical RCT-grade longevity effect estimate.

Within the longevity outcome class, no within-corpus disagreement can be enumerated because the included evidence base for this class contains only one source (Krekora 2026); the cross-study disagreement map flags no same-outcome non-orthogonal pairs for longevity. Accordingly, no positive-versus-null or dose-versus-dose disagreement can be cited, and any apparent tension must be deferred to cross-outcome contrasts in the broader synthesis. The two studies differ in both population (healthy adults versus a sarcopenia/mitochondrial dysfunction model) and direction, so any pooled inference must respect that heterogeneity.

Cross-Domain Synthesis

Cross-Domain Synthesis (cross-outcome tensions): The single most consequential tension in the sirtuin-intervention corpus is the discordance between mechanistic plausibility, repeatedly demonstrated in vitro and in animal models, and the comparatively thin set of human RCTs that test functional or hard clinical endpoints. The longevity-anchored mechanistic claim is grounded in yeast and animal work (Wu 2022, observational cohort framing of Sir2 copy-number effects on yeast lifespan) and in a murine model linking SIRT1 to heart failure (Krekora 2026, preclinical, longevity outcome class). Against this, the only directly-rated human RCT evidence with a clinical or functional endpoint in the corpus is Daneshi-Maskooni 2017 (cardiometabolic, direct), while every other clinical-endpoint signal — including Werida 2023 (contextual other, direct, positive) and Bo 2018 (contextual other, direct) — terminates at mechanistic/biomarker endpoints, which by methodological convention (Ioannidis 2005, surrogate endpoint caution) cannot be promoted to hard-outcome claims without additional evidence. The mechanistic-vs-clinical boundary condition is therefore narrow: sirtuin-pathway modulation is well documented at the molecular layer in rodents and in human biomarker studies, but whether modulating that pathway in humans extends healthspan remains an open question that current sources cannot adjudicate.

Another tension, evident in the cardio-metabolic and contextual outcome clusters, is that direct human evidence on sirtuin biomarker modulation is internally inconsistent rather than uniformly positive. The boundary condition that reconciles these signals is tissue- and context-specific: in diabetic or cardiometabolic stress states, sirtuin-1 upregulation can track with improved metabolic markers; in muscle undergoing glucocorticoid-induced catabolism, the same molecular event is associated with harm.

Another tension runs along the indirectness axis and is visible in the chronic-kidney-disease and periodontal evidence streams, where sirtuin-1 elevation tracks with disease presence rather than health. The boundary condition is therefore that higher measured sirtuin-1 does not, by itself, indicate that activating the pathway is beneficial; in damaged or inflamed tissue, elevated sirtuin may be a marker of homeostatic load. This tension is reinforced by Nguyen 2026 (deficiency prevalence, indirect) which shows endothelial sirtuins and mitochondrial function associating with testosterone status in middle-age and older men, suggesting sirtuin output is downstream of broader hormonal and metabolic context. Resolution would require intervention studies that lower or block sirtuin signaling in disease states to test whether elevated sirtuin is protective, neutral, or compensatory; current sources only support the associational reading.

Another tension, distinctive to this corpus, is that directness and outcome class track each other in a way that risks conflating very different evidence streams. The directly-rated human RCTs in the corpus are Daneshi-Maskooni 2017 (cardiometabolic, clinical/functional endpoint) and Werida 2023 and Bo 2018 (both contextual other, mechanistic/biomarker endpoint); every other study is either indirect, review, or preclinical. This means that when the synthesis is read as a whole, the cardiometabolic narrative is anchored by a single protocol-level RCT (Daneshi-Maskooni 2017) whose functional-endpoint readouts are not yet in the sources, while the contextual other narrative is anchored by two direct mechanistic RCTs. The 41-paper corpus therefore does not support 116 enumerated cross-study disagreements, nor any specific cross-study disagreement count beyond what the sources explicitly surface — which is a small, finite set of paired tensions (mechanism-vs-clinical across Werida 2023 / Bo 2018 / Daneshi-Maskooni 2017 against the indirect mechanistic and preclinical literature, plus the positive-vs-null direction split between Werida 2023 and Bo 2018, and the null-vs-negative direction split between Cho 2022 and Shi 2025 on muscle function). The boundary condition for the synthesis as a whole is therefore a precision claim: sirtuin-targeted interventions modulate molecular readouts consistently in the sources, but the human clinical-endpoint literature is too sparse to confirm or refute hard-outcome benefit, and any count of "cross-study disagreements" larger than what the sources enumerate should be treated as an artifact of the matching procedure rather than an evidence claim.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 41 curated reference papers, the evidence base for Sirtuin shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: muscle function, immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 41 included sources. The evidence-tier distribution is: B2 (n=35), A1 (n=3), D1 (n=1), C1 (n=1), B1 (n=1). By directness, the breakdown is: indirect (n=33), direct (n=3), review (n=3), protocol (n=1), mechanistic (n=1). 30 of 41 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: frail / sarcopenic adults; adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Additional corpus sources included animal/preclinical evidence; the curated corpus does not contain a long-term, hard-outcome randomized trial of sirtuin-targeted therapy in non-diabetic, community-dwelling older adults; longevity-relevant signals therefore reach the synthesis only through surrogate biomarker chains, and conclusions about lifespan extension cannot be drawn at the level of the human evidence base. Where hard outcomes appear at all — for example, cardiovascular endpoints in Nowak-Szwed 2025 (SIRT6 P < 0.001, SIRT4 P = 0.018) or frailty-adjacent muscle endpoints in Shi 2025 — they sit on top of biomarker cascades rather than event-driven follow-up, a pattern Ioannidis 2005 explicitly cautions against when surrogate associations are extended into clinical claims. The absence of a mortality or incident-morbidity trial means any cross-trial pooling of sirtuin effects onto aging endpoints is mechanistically motivated, not empirically demonstrated.

Several clinically relevant claims rest on mechanistic or animal-model evidence alone, so the boundary between bench observation and bedside recommendation cannot be drawn from this corpus. Translating these mechanistic anchors into anti-aging recommendations would require the assumption that sirtuin biology in Saccharomyces or C57BL/6 mice maps onto aging physiology in 70-year-old adults, an assumption the present evidence cannot test. Translational relevance to humans remains uncertain.

The corpus is heavily weighted toward patients with type 2 diabetes or overt cardiovascular disease, and toward short (8–12 week) supplementation protocols, which constrains external validity for the broader healthy-aging question.

Several clinically important signals are carried by a single trial in the corpus, so any replication check must be performed outside the present evidence base. Because these outcome channels are supported by a single source each, within-corpus replication is impossible, and the synthesis cannot rule out that any of these signals is study-specific rather than biology-general. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support sirtuin intervention aging effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 41 included sources on Sirtuin Intervention Aging Effects across 8 outcome classes and 116 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 41 curated reference papers, the evidence base for Sirtuin shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: muscle function, immune. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Werida 2023 and Bo 2018 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Noureldein 2015) emphasize convergent signals on Sirtuin Intervention Aging Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	null	direct interventional hard-endpoint gap
muscle function	0	2	negative, null	conflict-resolution gap
immune and inflammation	0	1	negative	direct interventional hard-endpoint gap
cardiometabolic	1	8	null, unclear	replication gap
deficiency prevalence	0	4	null	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	1	null	direct interventional hard-endpoint gap
immune and inflammation	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	2	20	null, positive	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P2	muscle function: conflict-resolution gap	0 direct and 2 indirect sources; direction profile: negative, null
P3	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: negative
P4	cardiometabolic: replication gap	1 direct and 8 indirect sources; direction profile: null, unclear
P5	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 4 indirect sources; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Sirtuin Intervention Aging Effects should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Tensions and Gaps

Additional corpus sources included animal/preclinical evidence; evidence-gap priority: The tension analysis separates claim-level disagreement counts from substantive cross-context evidence gaps. Biomarker-positive source-level findings are not pooled with mixed or null clinical-endpoint findings. The unresolved breadth therefore spans the reviewer-named adjacent contexts, and these contexts remain hypothesis-generating unless represented by retained direct clinical endpoint evidence. The manuscript reports 116 claim-level cross-study disagreements from the manifest; that number is a claim-level count, not an independently pooled source-pair count. Actually surfaced tensions include:

• Werida 2023 vs Nowak-Szwed 2025: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are positive versus unclear.
• Werida 2023 vs Garcia-Martinez 2023: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are positive versus null.
• Werida 2023 vs Wu 2022: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are positive versus unclear.

Evidence Snapshot

Directional coding note: Null or no extracted directional signal means no coded positive, negative, or mixed effect was extracted for that specific outcome class; it is not an absence-of-support finding. Positive, negative, mixed, unclear, and null are outcome-specific codes, so a bounded rationale can be supported by adjacent or different outcome evidence while another outcome remains null or unclear. Contextual claims contain bibliographic background, mechanism, methods, exposure definitions, or population context rather than effect-direction evidence. When an outcome-class summary uses no extracted directional signal, it should state the source proportion, such as X/Y sources, to avoid ambiguity.

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Additional corpus sources included animal/preclinical evidence; Werida 2023; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
• Daneshi-Maskooni 2017; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
• Bo 2018; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
• Noureldein 2015; tier=B1; directness=review; endpoint=immune; direction=negative; representative statistic=P < 0.001.
• Nowak-Szwed 2025; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Garcia-Martinez 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Wu 2022; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear.
• Zhang 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Nguyen 2026; tier=B2; directness=indirect; endpoint=deficiency prevalence; direction=null; representative statistic=P = 0.058.
• Nikooyeh 2021; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=null.

Source Outcome-Class Map

• Nowak-Szwed 2025: Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction: outcome=Cardiometabolic; directness=indirect; tier=B2.

• Garcia-Martinez 2023: Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• In animal/preclinical evidence, Wu 2022: The sirtuin family in health and disease: outcome=Cardiometabolic; directness=indirect; tier=B2.

• In animal/preclinical evidence, Zhang 2025: Epigallocatechin-3-Gallate from Green Tea Reduces Vascular Aging and Endothelial Cell Senescence by Modifying Autophagy and Ferroptosis through the Sirtuin 1 Signaling Pathway: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Werida 2023: Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial: outcome=Contextual Adjacent Evidence; directness=direct; tier=A1.

• Nguyen 2026: Endothelial Sirtuins and Mitochondrial Function Are Associated With Testosterone Status: Implications for Accelerated Vascular Aging in Middle‐Age and Older Men With Low Testosterone: outcome=Population / prevalence; directness=indirect; tier=B2.

• Nikooyeh 2021: The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes: outcome=Cardiometabolic; directness=indirect; tier=B2.

• Monge 2025: Sirtuin Expression in Age-Associated Hepatic Response to Burn Trauma: Translational and Clinical Insights From a Murine Model: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Wasserfurth 2021: Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Davari 2020: Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: a randomized, double blind, and controlled clinical trial: outcome=Immune and Inflammation; directness=indirect; tier=B2.

• Hwang 2020: Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Sayedyousef 2025: Taurine, Sirtuin-1 and TNF- α levels in different aged adults with periodontitis: a pilot study: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Gavia-Garcia 2026: Sechium edule var. nigrum spinosum (Chayote) Increases the mRNA Expression of Genes Encoding Sirtuins in Older Adults with Type 2 Diabetes Mellitus: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Liu 2014: The Sirtuin 3 Expression Profile Is Associated with Pathological and Clinical Outcomes in Colon Cancer Patients: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Cho 2022: Impact of Exercise Intensity on Systemic Oxidative Stress, Inflammatory Responses, and Sirtuin Levels in Healthy Male Volunteers: outcome=Muscle Function; directness=indirect; tier=B2.

• Yu 2016: The Prognostic and Clinicopathological Roles of Sirtuin-3 in Various Cancers: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Roggerio 2018: Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Sokrateva 2026: Effects of Citicoline-Based Supplementation on Lipid Peroxidation Markers and Sirtuin-1 Expression in Ischemic Stroke: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Rum 2025: The Relationship Between Aortic Tissue Sirtuin 1 Levels and Type A Aortic Dissections and Ascending Aortic Aneurysms: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Daneshi-Maskooni 2017: The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial: outcome=Cardiometabolic; directness=direct; tier=A1.

• In animal/preclinical evidence, Gonzalez-Fernandez 2019: Granulosa-Lutein Cell Sirtuin Gene Expression Profiles Differ between Normal Donors and Infertile Women: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Moin 2026: Deciphering the Role of Sirtuin‐1 Gene Polymorphism in Diabetic Nephropathy: A Systematic Review and Meta‐Analysis: outcome=Contextual Adjacent Evidence; directness=review; tier=B2.

• Lorente 2026: Association Between Salivary Sirtuin-1 Levels and Periodontitis: outcome=Cardiometabolic; directness=indirect; tier=B2.

• Rigdon 2024: Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults: outcome=Dosing and Pharmacokinetics; directness=review; tier=B2.

• Bodis 2019: Serum and follicular fluid levels of sirtuin 1, sirtuin 6, and resveratrol in women undergoing in vitro fertilization: an observational, clinical study: outcome=Population / prevalence; directness=indirect; tier=B2.

• Poniatowski 2026: Evaluation of Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) in serum and cerebrospinal fluid following fatal traumatic brain injury: outcome=Population / prevalence; directness=indirect; tier=B2.

• Lilja 2021: Five Days Periodic Fasting Elevates Levels of Longevity Related Christensenella and Sirtuin Expression in Humans: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Aghasi 2018: The effects of green cardamom supplementation on blood glucose, lipids profile, oxidative stress, sirtuin-1 and irisin in type 2 diabetic patients: a study protocol for a randomized placebo-controlled clinical trial: outcome=Contextual Adjacent Evidence; directness=protocol; tier=D1.

• Bo 2018: Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation: outcome=Contextual Adjacent Evidence; directness=direct; tier=A1.

• Bielach-Bazyluk 2025: Elevated Sirtuin 1 Levels in Patients with Chronic Kidney Disease, Including on Peritoneal Dialysis: Associations with Cardiovascular Risk and Peritoneal Fibrosis: outcome=Cardiometabolic; directness=indirect; tier=B2.

• Lapatto 2026: The effect of obesity and aging on NAD + /Sirtuin metabolism transcription and DNA methylation in subcutaneous adipose tissue of monozygotic twin pairs discordant for BMI: outcome=Cardiometabolic; directness=indirect; tier=B2.

• In animal/preclinical evidence, Shi 2025: Irisin Increases Sirtuin 1 to Improve Glucocorticoid-Induced Sarcopenia and Mitochondrial Dysfunction: outcome=Muscle Function; directness=indirect; tier=B2.

• In animal/preclinical evidence, Tsai 2021: Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency: outcome=Population / prevalence; directness=indirect; tier=B2.

• Chen 2015: Single Nucleotide Polymorphisms of the Sirtuin 1 (SIRT1) Gene are Associated With age-Related Macular Degeneration in Chinese Han Individuals: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• In animal/preclinical evidence, Shi 2020: Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis: outcome=Cardiometabolic; directness=indirect; tier=B2.

• Nyarady 2020: Effects of perinatal factors on sirtuin 3, 8-hydroxy-2′- deoxyguanosine, brain-derived neurotrophic factor and serotonin in cord blood and early breast milk: an observational study: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Budziak 2025: Can Sirtuin 1 Serve as a Therapeutic Target in Pulmonary Arterial Hypertension? A Comprehensive Review: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Biscetti 2024: Evaluation of sirtuin 1 as a predictor of cardiovascular outcomes in diabetic patients with limb-threatening ischemia: outcome=Cardiometabolic; directness=indirect; tier=B2.

• Sugishita 2024: Nicotinamide Adenine Dinucleotide (NAD)-Dependent Protein Deacetylase, Sirtuin, as a Biomarker of Healthy Life Expectancy: A Mini-Review: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2.

• Krekora 2026: Sirtuin 1 is a key molecular link between cellular senescence and heart failure: outcome=Longevity; directness=mechanistic; tier=C1.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Additional corpus sources included animal/preclinical evidence; severity 4 null vs negative: Shi 2025 vs Cho 2022; Shi 2025 (negative on muscle function) vs Cho 2022 (null on muscle function) — partial conflict
• Severity 4 null vs positive: Werida 2023 vs Bo 2018; Werida 2023 (positive on contextual other) vs Bo 2018 (null on contextual other) — partial conflict
• Severity 3 indirectness gap: Garcia-Martinez 2023 vs Werida 2023; Werida 2023 (direct, A1) vs Garcia-Martinez 2023 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Garcia-Martinez 2023 vs Bo 2018; Bo 2018 (direct, A1) vs Garcia-Martinez 2023 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Werida 2023 vs Monge 2025; Werida 2023 (direct, A1) vs Monge 2025 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Werida 2023 vs Sayedyousef 2025; Werida 2023 (direct, A1) vs Sayedyousef 2025 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Werida 2023 vs Sugishita 2024; Werida 2023 (direct, A1) vs Sugishita 2024 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Werida 2023 vs Zhang 2025; Werida 2023 (direct, A1) vs Zhang 2025 (indirect) on contextual other — direct vs indirect must be kept separate

Conclusion

For sirtuin intervention aging effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

References

• Nowak-Szwed 2025. Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction. Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-03013-y. PMID: 41462250.
• Garcia-Martinez 2023. Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes. International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24087422. PMID: 37108584.
• Wu 2022. The sirtuin family in health and disease. Signal Transduction and Targeted Therapy, 2022. DOI: 10.1038/s41392-022-01257-8. PMID: 36581622.
• Zhang 2025. Epigallocatechin-3-Gallate from Green Tea Reduces Vascular Aging and Endothelial Cell Senescence by Modifying Autophagy and Ferroptosis through the Sirtuin 1 Signaling Pathway. ACS Omega, 2025. DOI: 10.1021/acsomega.5c03880. PMID: 40918353.
• Werida 2023. Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial. BMC Endocrine Disorders, 2023. DOI: 10.1186/s12902-023-01511-2. PMID: 38001474.
• Nguyen 2026. Endothelial Sirtuins and Mitochondrial Function Are Associated With Testosterone Status: Implications for Accelerated Vascular Aging in Middle‐Age and Older Men With Low Testosterone. Aging Cell, 2026. DOI: 10.1111/acel.70457. PMID: 41986916.
• Nikooyeh 2021. The effect of daily intake of vitamin D-fortified yogurt drink, with and without added calcium, on serum adiponectin and sirtuins 1 and 6 in adult subjects with type 2 diabetes. Nutrition & Diabetes, 2021. DOI: 10.1038/s41387-021-00168-x. PMID: 34389701.
• Monge 2025. Sirtuin Expression in Age-Associated Hepatic Response to Burn Trauma: Translational and Clinical Insights From a Murine Model. Cureus, 2025. DOI: 10.7759/cureus.82663. PMID: 40400796.
• Wasserfurth 2021. Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training. Nutrients, 2021. DOI: 10.3390/nu13113824. PMID: 34836079.
• Davari 2020. Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: a randomized, double blind, and controlled clinical trial. Nutrition Journal, 2020. DOI: 10.1186/s12937-019-0518-3. PMID: 31901246.
• Hwang 2020. Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion. Biomolecules, 2020. DOI: 10.3390/biom10101414. PMID: 33036304.
• Sayedyousef 2025. Taurine, Sirtuin-1 and TNF-α levels in different aged adults with periodontitis: a pilot study. BMC Oral Health, 2025. DOI: 10.1186/s12903-025-06690-z. PMID: 40847336.
• Gavia-Garcia 2026. Sechium edule var. nigrum spinosum (Chayote) Increases the mRNA Expression of Genes Encoding Sirtuins in Older Adults with Type 2 Diabetes Mellitus. Molecules, 2026. DOI: 10.3390/molecules31071182. PMID: 41976223.
• Liu 2014. The Sirtuin 3 Expression Profile Is Associated with Pathological and Clinical Outcomes in Colon Cancer Patients. BioMed Research International, 2014. DOI: 10.1155/2014/871263. PMID: 25105144.
• Cho 2022. Impact of Exercise Intensity on Systemic Oxidative Stress, Inflammatory Responses, and Sirtuin Levels in Healthy Male Volunteers. International Journal of Environmental Research and Public Health, 2022. DOI: 10.3390/ijerph191811292. PMID: 36141561.
• Yu 2016. The Prognostic and Clinicopathological Roles of Sirtuin-3 in Various Cancers. PLoS ONE, 2016. DOI: 10.1371/journal.pone.0159801. PMID: 27483432.
• Roggerio 2018. Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration. Nutrients, 2018. DOI: 10.3390/nu10070937. PMID: 30037068.
• Sokrateva 2026. Effects of Citicoline-Based Supplementation on Lipid Peroxidation Markers and Sirtuin-1 Expression in Ischemic Stroke. Current Issues in Molecular Biology, 2026. DOI: 10.3390/cimb48030314. PMID: 41899465.
• Rum 2025. The Relationship Between Aortic Tissue Sirtuin 1 Levels and Type A Aortic Dissections and Ascending Aortic Aneurysms. Brazilian Journal of Cardiovascular Surgery, 2025. DOI: 10.21470/1678-9741-2024-0218. PMID: 41259217.
• Daneshi-Maskooni 2017. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. Trials, 2017. DOI: 10.1186/s13063-017-1979-3. PMID: 28592311.
• Gonzalez-Fernandez 2019. Granulosa-Lutein Cell Sirtuin Gene Expression Profiles Differ between Normal Donors and Infertile Women. International Journal of Molecular Sciences, 2019. DOI: 10.3390/ijms21010295. PMID: 31906251.
• Moin 2026. Deciphering the Role of Sirtuin‐1 Gene Polymorphism in Diabetic Nephropathy: A Systematic Review and Meta‐Analysis. Journal of Diabetes Research, 2026. DOI: 10.1155/jdr/5528647. PMID: 41624996.
• Lorente 2026. Association Between Salivary Sirtuin-1 Levels and Periodontitis. Journal of Clinical Medicine, 2026. DOI: 10.3390/jcm15041485. PMID: 41753173.
• Rigdon 2024. Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults. Clinical Pharmacology in Drug Development, 2024. DOI: 10.1002/cpdd.1488. PMID: 39587867.
• Bodis 2019. Serum and follicular fluid levels of sirtuin 1, sirtuin 6, and resveratrol in women undergoing in vitro fertilization: an observational, clinical study. The Journal of International Medical Research, 2019. DOI: 10.1177/0300060518811228. PMID: 30556451.
• Poniatowski 2026. Evaluation of Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) in serum and cerebrospinal fluid following fatal traumatic brain injury. International Journal of Legal Medicine, 2026. DOI: 10.1007/s00414-025-03626-8. PMID: 41107542.
• Lilja 2021. Five Days Periodic Fasting Elevates Levels of Longevity Related Christensenella and Sirtuin Expression in Humans. International Journal of Molecular Sciences, 2021. DOI: 10.3390/ijms22052331. PMID: 33652686.
• Aghasi 2018. The effects of green cardamom supplementation on blood glucose, lipids profile, oxidative stress, sirtuin-1 and irisin in type 2 diabetic patients: a study protocol for a randomized placebo-controlled clinical trial. BMC Complementary and Alternative Medicine, 2018. DOI: 10.1186/s12906-017-2068-6. PMID: 29343256.
• Bo 2018. Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation. Acta Diabetologica, 2018. DOI: 10.1007/s00592-017-1097-4. PMID: 29330620.
• Bielach-Bazyluk 2025. Elevated Sirtuin 1 Levels in Patients with Chronic Kidney Disease, Including on Peritoneal Dialysis: Associations with Cardiovascular Risk and Peritoneal Fibrosis. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26189033. PMID: 41009597.
• Lapatto 2026. The effect of obesity and aging on NAD + /Sirtuin metabolism transcription and DNA methylation in subcutaneous adipose tissue of monozygotic twin pairs discordant for BMI. International Journal of Obesity (2005), 2026. DOI: 10.1038/s41366-025-02007-w. PMID: 41491271.
• Shi 2025. Irisin Increases Sirtuin 1 to Improve Glucocorticoid-Induced Sarcopenia and Mitochondrial Dysfunction. Cells, 2025. DOI: 10.3390/cells14211675. PMID: 41227321.
• Tsai 2021. Upregulating sirtuin 6 ameliorates glycolysis, EMT and distant metastasis of pancreatic adenocarcinoma with krüppel-like factor 10 deficiency. Experimental & Molecular Medicine, 2021. DOI: 10.1038/s12276-021-00687-8. PMID: 34702956.
• Chen 2015. Single Nucleotide Polymorphisms of the Sirtuin 1 (SIRT1) Gene are Associated With age-Related Macular Degeneration in Chinese Han Individuals. Medicine, 2015. DOI: 10.1097/MD.0000000000002238. PMID: 26656366.
• Shi 2020. Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis. Theranostics, 2020. DOI: 10.7150/thno.49770. PMID: 33052223.
• Nyarady 2020. Effects of perinatal factors on sirtuin 3, 8-hydroxy-2′- deoxyguanosine, brain-derived neurotrophic factor and serotonin in cord blood and early breast milk: an observational study. International Breastfeeding Journal, 2020. DOI: 10.1186/s13006-020-00301-z. PMID: 32552911.
• Budziak 2025. Can Sirtuin 1 Serve as a Therapeutic Target in Pulmonary Arterial Hypertension? A Comprehensive Review. Molecules, 2025. DOI: 10.3390/molecules30183740. PMID: 41011644.
• Biscetti 2024. Evaluation of sirtuin 1 as a predictor of cardiovascular outcomes in diabetic patients with limb-threatening ischemia. Scientific Reports, 2024. DOI: 10.1038/s41598-024-78576-z. PMID: 39506067.
• Sugishita 2024. Nicotinamide Adenine Dinucleotide (NAD)-Dependent Protein Deacetylase, Sirtuin, as a Biomarker of Healthy Life Expectancy: A Mini-Review. Current Aging Science, 2024. DOI: 10.2174/0118746098319674240827104612. PMID: 39377386.
• Krekora 2026. Sirtuin 1 is a key molecular link between cellular senescence and heart failure. Frontiers in Molecular Medicine, 2026. DOI: 10.3389/fmmed.2026.1818104. PMID: 42125493.
• Noureldein 2015. Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. Diabetes Res Clin Pract, 2015. DOI: 10.1016/j.diabres.2015.05.043. PMID: 26105582.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.